Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

JuggernautRaider Sep. 3 at 2:11 PM

Sell $TSLA buy $TLSA Sell $SPCX buy $JNJ Hold $CGTX 🧠

0 · Reply

grampslol Sep. 3 at 12:27 PM

$MNKD poor @clan deluding himself as he tries to deceive the naive about furoscix...lol ... such a 🤡 $SPY $JNJ $AMGN

0 · Reply

CHARTBUSTER12 Sep. 3 at 12:16 PM

$JNJ good morning SEPT will be a hot sector for drug and bio stocks my friends. JNJ has some great things in the pipe line i do expect this to head over $300 watching two SMALL cap BIO company with possible treatment for cancer SLS,RNXT both i am hearing will have good results coming and big news in 2026. have a blessed rest of the week trading.

0 · Reply

clan Sep. 3 at 12:03 PM

$MNKD $JNJ $AMGN FUROSCIX ReadyFlow AutoInjector (for fluid buildup), by Mannkind Corporation's scParma division is: • Approved & • Being anticipated & • Ready & • Shipping & • Being prescribed & • Generating Sales & • Setting up to be hugely accretive & • Going to be good for all Mannkind. 💪 $SPY 🇺🇲 💪

0 · Reply

Outcomes Sep. 3 at 11:30 AM

$IBRX $MRNA $MRK $PFE $JNJ .....mRNA BAD.....'Turbo-cancers', etc. Data, Outcomes. PSS knows. SAVE THE CHILDREN. 🙏 https://x.com/MakisMedicine/status/2095370880108884069?s=20

0 · Reply

holdinglongerandstronger Sep. 3 at 7:21 AM

$SLS $JNJ $BMY $MRK Like I said on positive readout GPS Cancer Vaccine VERY LIKELY BO TARGET replacing 👀EXPIRING PATENTS..

0 · Reply

ElliottwaveForecast Sep. 3 at 12:50 AM

$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ

0 · Reply

JuggernautRaider Sep. 3 at 12:07 AM

$Z is dead money 🪦 $TNXP … dunno $JNJ is adequately valued i think 🤷‍♂️ $ALT woah baby 🧍‍♂️ 💉 💊 💪 🇺🇸

0 · Reply

Outcomes Sep. 2 at 9:20 PM

$IBRX $MRNA $MRK $PFE $JNJ https://x.com/stkirsch/status/2094989788919267745?s=46

0 · Reply

Outcomes Sep. 2 at 9:12 PM

$IBRX $MRNA.X $MRK $PFE $JNJ …alotta opinions on Makis, but WOW! https://x.com/makismedicine/status/2095156284513284405?s=46

1 · Reply

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

2026-09-02T11:35:52.000Z - 1 day ago

Johnson & Johnson assumed with a Buy at UBS

Aug 31, 2026, 5:08 PM EDT - 2 days ago

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Aug 27, 2026, 5:42 AM EDT - 7 days ago

China approves J&J's oral psoriasis pill, says drugmaker

Aug 24, 2026, 7:12 PM EDT - 9 days ago

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Aug 24, 2026, 6:33 PM EDT - 9 days ago

US FDA expands approval for J&J's drug for rare blood disorder

Aug 24, 2026, 12:20 PM EDT - 9 days ago

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

2026-08-19T22:09:27.000Z - 14 days ago

Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings

LIN

2026-08-17T10:16:04.000Z - 17 days ago

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG

Aug 13, 2026, 11:15 PM EDT - 20 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Aug 10, 2026, 4:27 PM EDT - 23 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

2026-08-07T19:33:43.000Z - 26 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Aug 6, 2026, 6:23 PM EDT - 27 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

Aug 4, 2026, 4:05 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 8:45 AM EDT - 4 weeks ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: Investor update

Aug 2, 2026, 8:00 AM EDT - 4 weeks ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Jul 30, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 5 weeks ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 5 weeks ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:38 PM EDT - 5 weeks ago

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:28 PM EDT - 5 weeks ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 5 weeks ago

Explainer: Can J&J finally put the talc litigation behind it?

Jul 28, 2026, 4:31 PM EDT - 5 weeks ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 5 weeks ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 1:03 AM EDT - 5 weeks ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 5 weeks ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 5 weeks ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 5 weeks ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 5 weeks ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 5 weeks ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 6 weeks ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 6 weeks ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 7:21 AM EDT - 6 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 6 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 6 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 7 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 7 weeks ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 7 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 7 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 7 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 7 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 7 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 7 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 7 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 7 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 1 month ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 1 month ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 2 months ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 2 months ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

JuggernautRaider Sep. 3 at 2:11 PM

Sell $TSLA buy $TLSA Sell $SPCX buy $JNJ Hold $CGTX 🧠

0 · Reply

grampslol Sep. 3 at 12:27 PM

$MNKD poor @clan deluding himself as he tries to deceive the naive about furoscix...lol ... such a 🤡 $SPY $JNJ $AMGN

0 · Reply

CHARTBUSTER12 Sep. 3 at 12:16 PM

0 · Reply

clan Sep. 3 at 12:03 PM

0 · Reply

Outcomes Sep. 3 at 11:30 AM

$IBRX $MRNA $MRK $PFE $JNJ .....mRNA BAD.....'Turbo-cancers', etc. Data, Outcomes. PSS knows. SAVE THE CHILDREN. 🙏 https://x.com/MakisMedicine/status/2095370880108884069?s=20

0 · Reply

holdinglongerandstronger Sep. 3 at 7:21 AM

$SLS $JNJ $BMY $MRK Like I said on positive readout GPS Cancer Vaccine VERY LIKELY BO TARGET replacing 👀EXPIRING PATENTS..

0 · Reply

ElliottwaveForecast Sep. 3 at 12:50 AM

0 · Reply

JuggernautRaider Sep. 3 at 12:07 AM

$Z is dead money 🪦 $TNXP … dunno $JNJ is adequately valued i think 🤷‍♂️ $ALT woah baby 🧍‍♂️ 💉 💊 💪 🇺🇸

0 · Reply

Outcomes Sep. 2 at 9:20 PM

$IBRX $MRNA $MRK $PFE $JNJ https://x.com/stkirsch/status/2094989788919267745?s=46

0 · Reply

Outcomes Sep. 2 at 9:12 PM

$IBRX $MRNA.X $MRK $PFE $JNJ …alotta opinions on Makis, but WOW! https://x.com/makismedicine/status/2095156284513284405?s=46

1 · Reply

focafoca99 Sep. 2 at 9:04 PM

$JNJ engaged to present at the Deutsche Bank 2026 Healthcare Summit on Sep 17. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-participate-35daf7

0 · Reply

TalkMarkets Sep. 2 at 9:02 PM

#Stocks Snap Three-Day Slide As Yields Stabilize Mentions: $NVDA $JNJ $SPY $QQQ $DIA https://talkmarkets.com/article/stocks-snap-three-day-slide-as-yields-stabilize-1788382900

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 7:20 PM

$AZN $JNJ $MRK $PFE $SLS Shorts are pushing Dr. Stergiou to the brink and he might potentially release the GPS CURATIVE KRAKEN after the bell and wipe out cancer along with the shorts! ✌️🙏❤️‍🩹

0 · Reply

Nosh Sep. 2 at 7:15 PM

$JNJ $PG starters yesterday.

1 · Reply

vermigli Sep. 2 at 5:13 PM

$JNJ up over 32% YTD. UBS sets price target at $320. https://seekingalpha.com/news/4639561-jj-stock-at-all-time-high-ubs-assumes-buy 1 year dividend growth rate TTM is 4.38%. JNJ has grown the dividend for 63 consecutive years.

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 5:01 PM

$AZN $JNJ $MRK $PFE $SLS What does this mean for Big Pharmaceutical Suitors? GPS Curative 3 year plus Maintenance schedule for potentially 20+ WT1 cancers= $50 Billion annual peek sales and Dethrone patent expiring 2028 Keytruda as # 1 selling drug on the planet. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 4:57 PM

$SLS $JNJ $AZN $MRK $PFE The real breakthrough is dual MHC Class I and Class II activation. Multivalency also ensures the cancer can't run. Together, they create a self-sustaining, polyclonal, living defense system inside the patient, one that hunts WT1-expressing cells for the rest of their life. And the 80% GPS responders? They aren't likely just surviving. They are functionally cured. Not managed. Not in fragile remission. CURED. With infinite dosing their T cells are still patrolling YEARS later. No cytokine storms. No need for a donor search. An off-the-shelf injection that reprograms immunity itself. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 4:34 PM

$AZN $JNJ $LLY $MRK $SLS GPS Regal Pivotal Registrational Phase 3 Study Breakthrough results in AMLCR2/CRp2 is master key to unlock 20+ WT1 GPS Ad Infinitum Curative Platform. 👇 ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 4:18 PM

$AZN $JNJ $LLY $MRK $SLS With Warrants Extinguished and $SLS HTB/NTB (Hard To Borrow) (None To Borrow) 56 Million shares short, this is going to get really ugly for shorts in to the close EOD. Margin calls coming. 🔥 ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 4:11 PM

$AZN $JNJ $LLY $MRK $SLS 🤩 Major Blocks hitting the ASK now. 👇 ✌️❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 4:05 PM

$AZN $JNJ $LLY $MRK $SLS Massive Blocks going through Level 2 right now. 👇 ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Sep. 2 at 3:56 PM

$AZN $JNJ $LLY $MRK $SLS The American Association for Cancer Research (AACR) is widely considered one of the most prestigious and authoritative professional organizations in the global medical and scientific community.Reputation and ScaleWorld's Largest: Founded in 1907, it is the world's first and largest professional organization dedicated to advancing cancer research, boasting over 65,000 members across 143 countries and territories.Elite Membership: Its roster includes hundreds of Fellows of the AACR Academy, featuring dozens of Nobel laureates.High-Impact PublicationsTop-Tier Journals: The AACR publishes 10 peer-reviewed scientific journals, including highly influential and high-impact titles like Cancer Discovery, Cancer Research, and Clinical Cancer Research.Authoritative Forums: These journals are regarded as premier venues for publishing groundbreaking basic, translational, and clinical oncology research. ✌️🙏❤️‍🩹

0 · Reply

Market Cap	653.54B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.48
Forward PE	22.90
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	7,913,000
Avg Vol	7,584,166
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	66%
Beta	0.24
Analysts	Strong Sell
Price Target	$276.29